Abstract:Background/Objectives: The incidence of head and neck squamous cell carcinoma (HNSCC), currently ~800,000 cases per year worldwide, is rising. Radiotherapy remains a mainstay for the treatment of HNSCC, although inherent radioresistance, particularly in human papillomavirus (HPV)-negative disease subtypes, remains a significant barrier to effective treatment. Therefore, combinatorial strategies using drugs or inhibitors against specific cellular targets are necessary to enhance HNSCC radiosensitivity to lead to an improvement in patient outcomes. Given that radiotherapy acts through targeting and damaging DNA, a common strategy is to focus on enzymes within DNA-dependent cellular pathways, such as DNA damage repair. Methods: Here, we have employed a 3D spheroid model of HNSCC (FaDu) in combination with a targeted drug screen to identify novel radiosensitisers that suppress tumour growth. Results: We identified that histone deacetylases (HDACs) were prominent candidates, and subsequently identified that the HDAC inhibitors mocetinostat and pracinostat, as well as the combined HDAC–epidermal growth factor receptor inhibitor CUDC-101, were effective at radiosensitising cell models of HNSCC (FaDu, A253, UMSCC11b) through their impact on both spheroid growth and clonogenic survival assays. We also demonstrated that this combinatorial strategy leads to inhibition of the repair of DNA double-strand breaks through the neutral comet assay and γH2AX foci analysis using immunofluorescence microscopy, providing a mechanism of action through which HDAC inhibition functions in HNSCC radiosensitisation. Conclusions: We believe that this approach should be further investigated in preclinical models, in order to realise the full therapeutic potential of HDAC inhibition for the radiosensitisation of HNSCC, eventually leading to improved patient treatment efficacy and outcomes.

Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

KAP1 Deacetylation by SIRT1 Promotes Non-Homologous End-Joining Repair.

Author Correction: the Bromodomain Containing Protein BRD-9 Orchestrates RAD51–RAD54 Complex Formation and Regulates Homologous Recombination-Mediated Repair

A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.

Acetylation of 53BP1 Dictates the DNA Double Strand Break Repair Pathway

PDHE1α in DNA Damage Repair: a Critical Chromatin Acetylation Regulator

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

RAP80-directed Tuning of BRCA1 Homologous Recombination Function at Ionizing Radiation-Induced Nuclear Foci.

Acetylation-dependent Function of Human Single-Stranded DNA Binding Protein 1

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.

Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

Targeting DNA damage response pathways in cancer

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Untousling the Role of Tousled-like Kinase 1 in DNA Damage Repair

HDAC Inhibitors Can Enhance Radiosensitivity of Head and Neck Cancer Cells through Suppressing DNA Repair